with Immune-Onc supplying IO-108 and retaining worldwide rights to the antibody. Approved by the US Food and Drug Administration for HCC, the combination of atezolizumab and bevacizumab received ...

Galux Inc., a South Korean startup specializing in AI-driven protein therapeutics design, has published a study showcasing ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard ... the 18 patients who received the standard regimen ...

Tecentriq is a monoclonal antibody designed to bind with PD-L1 ... interactions with both PD-1 and B7.1 receptors. In this way, atezolizumab may enable the reactivation of T-cells, though it ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

Vilastobart is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody designed ... in combination with atezolizumab (Tecentriq ®) at 1200 mg ...

and developability comparable to the commercial therapeutic antibody Atezolizumab. Additionally, antibodies designed for EGFR(S468R) displayed exceptional specificity, precisely distinguishing ...

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in ... to develop novel tumor-activated, antibody-based immunotherapies ...